During the last six years, several innovative, systemic therapies for the treatment of metastatic malignant melanoma (MM) have emerged. Conventional chemotherapy has been superseded by novel first-line therapies, including systemic immunotherapies (anti-CTLA4 and anti-PD1; authorization of anti-PDL1 is anticipated) and therapies targeting specific mutations (BRAF, NRAS, and c-KIT). Thus, treating physicians are confronted with new challenges, such as stratifying patients for appropriate treatments and monitoring long-term responders for progression. Consequently, reliable methods for monitoring disease progression or treatment resistance are necessary.
Introduction
The incidence of malignant melanoma (MM) has risen persistently during the last few decades, particularly in older age groups (> 50 years) [1] . According to GLOBOCAN, more than 232,000 new cases of melanoma of the skin occurred worldwide in 2012, with approximately 55,500 reported deaths [2] . Depending on the tumor stage, treatment options include surgery of the primary tumor and metastases and, in cases of extensive, inoperable disease, radiation therapy and/ or systemic immune/targeted/chemotherapies [3, 4] . These procedures are followed by regular follow-up visits to screen the patient for recurrence, metastases and tumor markers in the blood [5] . During the last decade, numerous new therapeutic options for the treatment of metastatic MM have emerged. Conventional chemotherapy has been superseded by novel first-line therapies, including systemic immunotherapies (anti-CTLA4 and anti-PD1, with authorization of anti-PDL1 anticipated) and therapies targeted against specific mutations (BRAF, NRAS, and c-KIT). Treating physicians are therefore confronted with new challenges, including stratifying patients for appropriate treatments, monitoring long-term responders for recurrence and screening patients with no evidence of disease (NED) for progression. Consequently, reliable methods for monitoring disease progression or treatment resistance are necessary.
The ideal tumor marker is specific for a single tumor entity and measurably secreted into the peripheral blood. It should only be detectable in the presence of the tumor and reflect tumor proliferation before causing metastases. The blood quantity should correlate with tumor burden, whereas serum concentration changes should mirror disease progression as well as treatment responses [6] [7] [8] [9] .
The melanoma tumor marker S100B is present not only in melanoma cells but also in various normal tissues [10] and therefore harbors the risk of nonspecific elevation. Technical handling of the sample and medical conditions such as neuronal tissue damage or destruction may lead to false-positive test results [10] . Consequently, some patients will undergo unnecessary radiological diagnostic examinations, which consume resources and cause emotional distress for the patients. Thus, liquid biopsy results may be useful as novel biomarkers with sufficient sensitivity to serve as a predictive indicator and to guide therapeutic decisions, particularly for patients with (NED) or minimal residual disease (MRD) status, i.e. stage III or IV after R0 resection or those with a complete response to other treatment.
Circulating tumor cells
Localized and advanced cancers may generate circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) that are detectable in the blood. Frequent blood sampling is usually accepted by patients; thus, the detection of CTCs in peripheral blood appears to be a promising diagnostic tool [11] . Studies on the analysis of CTCs from patients with advanced malignancies were reported starting in the 1960s [12] . Over the last decade, this area of research has attracted immense interest. To date, CTC analysis has shown promising results in establishing the tumor response to chemotherapy and in the prognosis of patients with various metastatic malignancies. These tumor entities include cancers of the bladder, breast, liver, lung, ovaries, pancreas, prostate, stomach, colon and rectum as well as Merkel cell carcinoma and MM [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . For patients with metastatic breast, colorectal, or prostate cancer, a significant association between the CTC count and prognosis has been demonstrated, leading to FDA approval of the CellSearch™ CTC system (Menarini Silicon Biosystems, San Diego, CA, USA) for these three entities in 2008.
In breast cancer patients, CTCs may be found in 36 % of NED patients, including those at 7-22 years after mastectomy (dormancy candidates) [28] . These CTCs are apparently shed from persisting tumors, probably from micro-metastases; however, there appears to be a favorable balance between tumor replication and cell death for up to several decades [28] . Thus, it is conceivable that these long-lasting CTCs do not represent relevant markers for progression, and the implications of persisting CTCs in NED patients remain under investigation. Furthermore, the number of cells that are shed from the primary tumor and remain in circulation is subject to debate [11, 29, 30] . Only a subpopulation of cells from a primary tumor is able recognized to give rise to metastases [31, 32] , because most tumor cells entering the peripheral bloodstream are either rapidly removed (e.g. by anoikis) or remain quiescent [14, 31, 33] . Thus, the presence of CTCs does not reliably predict the development of metastasis. More than 40 years ago, Fidler et al. showed that 24 hours after the intravenous injection of radiolabeled B16 melanoma cells into mice, although 0.1 % of these cells were still alive, only 0.01 % of these cells were able to cause lung metastases [31] .
Over the previous ten years, numerous assays for the direct detection of CTCs have been developed that allow for the analysis of CTCs at the single-cell stage in the peripheral blood [34] . Depending on the detection method, a few disadvantages warrant consideration (Table 1) : Flow cytometry does not allow simultaneous visual assessment of the morphological features of the cells. Thus, a true separation of tumor cells from other cells or nonspecific events may be difficult [35] . Density gradient purification with interphase recovery includes several washing steps, which may lead to significant loss of key cells [36] . Magnetic bead enrichment, which is used by the FDA-approved CellSearch™ system, is dependent on key cell numbers in a correct volume and requires a certain level of surface antigen expression to maintain the cell in the magnetic field. Furthermore, because magnetic bead enrichment may lead to significant cell destruction, leaving mainly cell debris, it is thus susceptible to selection bias [37] [38] [39] [40] . Most currently available CTC assays are based on detection via antibodies directed against epithelial markers, e.g. the epithelial cell adhesion molecule EpCAM (CD137) and/or various cytokeratins (CKs). Blood cells usually do not express epithelial markers because of their mesenchymal origin. Discrimination between the CTCs of epithelial cancers and blood cells is therefore possible. However, EpCAM is not only expressed on tumors of epithelial origin but also on some dendritic cells and normal epithelia [41, 42] . Benign diseases of the gastrointestinal tract and menstruation have been shown to potentially lead to a significant epithelial cell component in the peripheral blood, even without underlying malignancy [43] . Furthermore, during progression of the epithelial-to-mesenchymal transition (EMT), both Ep-CAM and CK are down-regulated as part of an oncogenic pathway, leading to further detection difficulties [25] . Two other exciting methods have been developed at the Harvard Massachusetts General Hospital. The microfluidic platform "CTC-chip" separates viable CTCs from peripheral blood by direct interaction of CTCs with EpCAM-coated microposts [14] . The "cluster-chip" traps CTC clusters in a specifically designed chip [25] . Both methods omit processing or pre-labeling of samples and have the advantage of gathering viable CTCs. Regarding its dependence on EpCAM-expressing cells, the first version of the "CTC-chip" has the same disadvantages as discussed above; however, according to the manufacturer, it is possible to coat the microposts with antibodies other than EpCAM.
The appearance of CTCs in the blood of MM patients and its association with tumor burden and therapeutic response has been demonstrated in various studies using different assays and methodologies (reviewed in [44] and [45] ). An association between the detection of CTCs and disease stage has been demonstrated [46] ; however, it was not superior to S100B for surveillance of stage II and III patients [47] . In stage III patients, the association between detection of CTCs and clinical outcome differed depending on the time of analysis (pre-or post-treatment) and the markers used [48] [49] [50] . As a reflection of different detection methods, the results of several studies were inconsistent, including those in stage IV patients [19, 46, 49, 51, 52] . Melanoma cells do not express epithelial markers such as EpCAM or CK. Instead, the application of specific melanoma antigens has shown promising results, for example tyrosinase, melanoma antigen gene-A3 family (MAGE-A3), melanoma antigen recognized by T cells (MART-1), paired box 3 (PAX3), polypeptide N-acetylgalactosaminyltransferase (GalNac-T), melanoma cell adhesion molecule (MCAM; syn. MUC18, MelCAM or CD146) and the human high-molecular weight melanoma-associated antigen (HMW-MAA) [53, 54] . As the most frequently used CTC detection system, CellSearch™ uses magnetic beads labeled with MCAM as a first magnetic capture step followed by a second staining step using 4ʹ,6-diamidino-2-phenylindole (DAPI) (staining of cell nucleus) and an antibody cocktail including anti-CD34 (endothelial cells), anti-CD45 (leukocytes) and anti-HMW-MAA (melanoma cells). Only cells positive for MCAM, DAPI and HMW-MAA and negative for CD34 and CD45 are considered to be melanoma cells. In 26-33 % of patients with metastatic melanoma, the CellSearch™ system detected more than two viable cells per 7.5 ml of blood, thereby segregating patients with a poor prognosis [52, 55, 56] . However, not all melanomas express MCAM and HMW-MAA, and benign lesions that express HMW-MAA or MCAM exist [57] [58] [59] . Thus, the use of antigen-dependent cell capture always harbors the risk of nonspecific staining. None of the aforementioned antibodies is unique for melanoma cells. Tyrosinase and MART-1 are also expressed on benign melanocytes and nevi. MAGE-3 is expressed on spermatocytes and on various malignancies (non-small cell lung cancer and hematological malignancies, among 
Cell-free ctDNA
In addition to the direct detection of CTCs, indirect detection assays are based on the detection of nucleic acid contents released by tumor cells into the blood. To date, novel detection technologies have significantly improved the sensitivity and specificity of the detection assays. Nearly 50 years ago, Mandel and Métais demonstrated the existence of cell-free DNA (cfDNA) in the circulation of healthy individuals [60] . During the previous decade, the detection and phenotyping of cell-free circulating nucleic acids shed by malignant tumors, including ctDNA and RNA species (mRNA, microRNA), have been steadily augmenting the clinical utility of liquid biopsy [61] . By definition, the term biopsy (bios: life and opsis: see) implies the isolation and subsequent cytopathological analysis of intact cells, not merely that of fragments. Thus, the term 'liquid sample' would be preferable. The detectable ctDNA fragments are usually derived from apoptotic or necrotic cells that are shed from malignancies, and may be isolated from peripheral blood. Cancer patients usually exhibit higher median blood levels of cfDNA than healthy controls or individuals with noncancerous comorbidity (e.g. 6,000 vs. 2,400 vs. 3,800 copies/ ml, respectively) [62] . The analysis of ctDNA provides three parameters that may be correlated with clinical outcome: 1) the total quantity of ctDNA in the sample, 2) the molecular fingerprint of the ctDNA by mutation detection, and 3) the quantification of mutant copies. Its use as a biomarker is of prognostic value in several cancers [26, 63, 64] with a sensitivity ranging from 26-100 % depending on the disease, stage, detection method and genetic markers examined [65, 66] . In melanoma patients, the analysis of ctDNA including the detection of typical mutations (BRAF, NRAS) [67] , microsatellite alterations [2, 68] and epigenetic markers such as methylated DNA [51, 69, 70] reached detection rates of up to 80 % [71, 72] .
In blood, ctDNA appears to be more unstable than normal DNA, and its clearance mechanisms remain incompletely understood. Serial blood plasma analyses of a single individual following tumor surgery revealed a ctDNA half-life of 114 min [26] . In contrast, the half-life of fetal circulating DNA in eight women shortly after delivery was 16.3 min (range 4-30 min) [73] . Other studies that analyzed the kinetics of ctDNA using next-generation sequencing showed biphasic elimination with half-lives of approximately 1 h for the first phase and 13 h for the second phase. The main fraction of ctDNA is presumably cleared by hepatic and renal elimination [74] . However, the full details of renal clearance are not known. Circulating fetal DNA is not secreted into the urine [25] . In contrast, in some patients with colorectal or pancreatic cancer, mutant K-ras gene sequences were detectable in the urine [63] . Therefore in those cases, at least part of the extracellular DNA was secreted into the urine.
These aspects require special attention because the rapid processing of blood samples and use of special additives are critical for ctDNA detection, and because clearance might be prolonged in patients with renal/hepatic insufficiency, leading to the impression of a higher ctDNA burden. Due to the low abundance of ctDNA, its detection requires highly sensitive and specific techniques. Standard Sanger sequencing is not sufficiently sensitive. Recently, highly specific ctDNA detection and quantification methods have been developed with declared sensitivity rates of 0.01 % or even lower. Three of the most frequently used techniques are digital PCR (dPCR), BEAMing and allele-specific ligation PCR (LPCR) ( Table 2 ). Digital PCR refines the advantages of standard PCR with the use of multiple separate reaction partitions, increasing precision and decreasing error rates [75] . The PCR reaction proceeds in a micro-well plate, a capillary, a drop of water in oil emulsion or in array modules using miniaturized chambers. BEAMing combines emulsion dPCR with magnetic beads and flow cytometry [76] . Ligation PCR allows for allele discrimination using primers that anneal to specific alleles followed by PCR amplification [77] . Amplicon deep sequencing [78] or hybrid-capture deep sequencing [79] are newly developed targeted sequencing strategies. Targeted sequencing covers thousands of amplicons in ctDNA in one assay read [79, 80] . Due to a user-defined target sequence, it provides broad utilization across different tumor entities, allowing the detection of sub-clonal mutations or changes in clonal composition over time. Its disadvantages include the costs, the time needed to process the samples and the substantial volume of resulting data to process. Furthermore, its use requires specific strategies such as barcoding and target capture to reach a sensitivity < 1 % and to avoid false-positive results [81] . To date, dPCR appears to be one of the most suitable techniques for the detection and monitoring of mutations, such as BRAFV600E in MM, in a clinical setting. It permits highly sensitive detection of allele variants down to a resolution of 0.005 %, and it is cost efficient and rapid while detecting up to four different mutations simultaneously [82] . Digital PCR (dPCR) -quantification of a target DNA sequence in a DNA sample -highly diluted DNA sample such that after running many PCR reactions in parallel, some of them will not receive a single molecule of the target DNA; the target DNA concentration is calculated using the proportion of negative outcomes -each DNA template is amplified separately in droplets and quantified, thereby increasing precision and decreasing error rates -simultaneous detection of different mutations -cost efficient and rapid -particular sequences flanking the sequence of interest must be known -danger of contamination -amplification errors will be further amplified BEAMing -combination of emulsion dPCR with magnetic beads and flow cytometry allowing for further separation and purification -potential to detect even very rare mutant templates at copy ratios greater than 1 : 10,000
-each DNA template is amplified separately on beads and quantified -particular sequences flanking the sequence of interest must be known -danger of contamination -amplification errors will be further amplified Allele-specific ligation PCR (LPCR) -based on single-nucleotide variations -use of allele-specific primers allows for allele discrimination -prior knowledge of a DNA sequence and allele differences required -danger of contamination -amplification errors will be further amplified
Amplicon deep sequencing Hybrid-capture deep sequencing -newly developed targeted sequencing strategies -thousands of amplicons in ctDNA covered with one assay read -broad utilization across various tumor entities -detection of sub-clonal mutations or changes in clonal composition over time -highly time-and resource-consuming -tremendous amount of data to process Extracellular vehicles (EV) such as exosomes have also been identified as putative biomarkers in various cancer entities [83, 84] . Exosomes are derived from the endosomal system, are 50-100 nm in size and are secreted by living cells, particularly malignant cells but also by normal cells such as red blood cells, dendritic cells, lymphocytes and platelets [84, 85] . They provide a cell-to-cell horizontal transfer/exchange of properties important for cross-talk among cells. Depending on the cell of origin, exosomes shuttled between cells contain diverse cellular proteins and nucleic acids, as well as endogenous short RNAs (esRNA) and microRNAs (miRNA) [86, 87] . Both EV and miRNA are attracting interest as diagnostic targets and particularly as novel targets in various cancer entities [88, 89] . Data from a melanoma mouse model suggest that microvesicles containing ctDNA and RNA might direct the metastatic behavior of a cancer [90] . Moreover, miRNAs have been shown to play important roles in drug-resistance mechanisms in MM [91] . Thus, the targeting or modulation of miRNAs might become a promising approach for managing therapy resistance.
Limitations of liquid biopsy in routine diagnostics
The clinical implications of liquid biopsy in routine diagnostic testing of melanoma patients remain controversial. First of all, it should be emphasized that apart from demonstrating the presence of the same mutations in the primary tumor and in the CTCs/ctDNA, none of the currently available CTC/ctD-NA PCR-based assays unequivocally confirm the affiliation with the tumor. Thus, it remains unclear whether the detected CTCs/ctDNA clearly pertain to the tumor under treatment. Furthermore, melanoma is a heterogeneous tumor that often consists of several sub-clones [92] . Theoretically, each individual sub-clone may give rise to CTCs/ctDNA harboring different genetic aberrations. Thus, despite of detection of BRAFV600E mutation-harboring CTCs or ctDNA that are detectable in the blood of a stage IV melanoma patient, might have arisen from a predominant clone or a minor sub-clone. However, the detection of increasing numbers of MCAM + HMW-MAA + cells in the blood of a stage IV melanoma patient probably indicates progressive disease. In contrast, the detection of MCAM + HMW-MAA + cells in a melanoma patient with NED or MRD status might predict disease progression but might also reflect benign nevi expressing MCAM and HMW-MAA. However, methods such as FISH or single-cell PCR might help further distinguishing nevi cells from melanoma cells.
In stage IV BRAFV600 mutation-positive melanoma, the detection of ctDNA indicated inferior progression-free and overall survival [72] . In stage III/IV melanoma with evidence of disease, changes in CTC/ctDNA amount, tumor burden and treatment response were well correlated [44, 71, 93] . By contrast, several other studies did not demonstrate such an association [94] [95] [96] [97] . Furthermore, the association between ctDNA quantity and treatment response was demonstrated in patients treated with targeted therapies and after adoptive T-cell transfer [97] , but not in patients treated with immunotherapies [71] . Interestingly, analysis of ctDNA levels of a single patient did not reliably detect brain-only metastatic progression, which was consistent with previous studies on ctDNA and the blood-brain barrier [66] .
The detection of increased amounts of CTCs/ctDNA may precede the radiological detection of disease progression [12, 71, 98, 99] . Moreover, such detection may aid in monitoring the response or development of resistance to targeted therapies [71] . Thus, decreasing numbers of BRAF-V600E-harboring CTCs/ctDNA in a patient undergoing treatment (for example, surgery, radiation, or systemic therapy) will most likely reflect a treatment response. Wherease in stage I/II and NED melanoma patients the significance of CTCs/ctDNA is unknown, and such testing is therefore not recommended outside clinical trials. An additional challenge is the absent tumor specificity of mutations. For example, mutant BRAF has not only been detected in MM (40-60 %) [100] but also in other malignancies, including hairy cell leukemia (100 % of classic cases) [101] , papillary thyroid cancer (55-67 %) [102, 103] , colorectal cancer (5-10 %) [104, 105] , biliary tract tumors (6 %) [106] , multiple myeloma (5 %) [107] , non-small cell lung cancer (up to 4 %) [108] and to a lesser extent in lymphoproliferative and myeloproliferative disorders, sarcomas, ependymomas, as well as liver, stomach, esophageal, breast and ovarian cancers [109] . It has also been observed in glioma (10-60 %) [110] , gastrointestinal stromal tumor (GIST) (7 %) [111] and in rare histiocytic disorders such as Erdheim-Chester disease (54 %) and Langerhans cell histiocytosis (38 %) [112] . Therefore, additional malignancies must always be considered. Furthermore, cancer-associated mutations occur with increasing age, even in healthy individuals who will never develop a malignancy during their lifetime [113] . Therefore, older patients are at increased risk of false-positive test results. Perhaps more importantly, 82 % of benign melanocytic nevi carry BRAF mutations [114] . Thus, the detection of mutant BRAF is not unique to melanoma.
Although the clinical relevance of CTCs and ctDNA for disease monitoring in patients with metastatic disease is well established and thus currently entering routine clinical diagnostic use, the role of these biomarkers in early-stage cancer patients remains to be investigated [13] . Randomized clinical trials are needed to demonstrate the clinical utility of CTC/ctDNA detection in MM patients with early-stage disease. For NED melanoma patients, a reliable, specific, and sensitive biomarker that is superior to S100B and precedes radiological results is important for clinical decision-making. The latter includes stratification of MM patients at high risk for relapse who might benefit from an adjuvant therapy and appropriate scheduling of follow-up examinations. Ideally, this biomarker would predict progression and response or relapse with targeted therapy, and would thus avoid subsequent unnecessary diagnostic procedures.
In summary, the use of liquid biopsy in routine diagnostic testing remains limited due to the following concerns: 
Conclusion and future outlook
The translation of liquid biopsy into clinical use for MM patients will depend on efforts proving the significance of these techniques in larger patient cohorts such as CANCER-ID (www.cancer-id.eu). It will be exciting to track these fascinating techniques as they become integrated into routine diagnostic procedures.
